The Role of Chemotherapy in Prostate Cancer

Video

William Kevin Kelly, DO, discusses the role of chemotherapy in castration-resistant prostate cancer.

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the role of chemotherapy in castration-resistant prostate cancer (CRPC).

Clinical Pearls

  • Chemotherapy has been used to treat CRPC for a long time
  • Docetaxel has become a key chemotherapy agent used to treat CRPC for the last decade
  • Physicians have tried to use docetaxel with other newer targeted agents, but combining agents with docetaxel has not shown any clinical benefit
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content